1-(4-fluorobenzyl)-2-methyl-1H-benzimidazole-5-carboxylic acid | 947413-11-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(4-fluorobenzyl)-2-methyl-1H-benzimidazole-5-carboxylic acid
• 英文别名: 1-[(4-Fluorophenyl)methyl]-2-methylbenzimidazole-5-carboxylic acid
• CAS: 947413-11-8
• 化学式: C₁₆H₁₃FN₂O₂
• 分子量: 284.29
• InChiKey: FTSRUBAKMZNSRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-fluorobenzyl)-2-methyl-1H-benzimidazole-5-carboxylic acid 、 (R)-(+)-1-苯丙胺 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 1-[(4-fluorophenyl)methyl]-2-methyl-N-[(1R)-1-phenylpropyl]-1H-benzimidazole-5-carboxamide
  参考文献：
  名称：

  Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist

  摘要：

  The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a ligand-activated nuclear receptor, thought to play a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation. A novel benzimidazole series of centrally penetrant PPAR gamma partial agonists has been identified. The optimization of PPAR gamma activity and in vivo pharmacokinetics leading to the identification of GSK1997132B a potent, metabolically stable and centrally penetrant PPAR gamma partial agonist, is described. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.088
• 作为产物：
  描述：

  4-(4-Fluoro-benzylamino)-3-nitro-benzoic acid methyl ester 在 tin(II) chloride dihdyrate 、 溶剂黄146 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 38.5h， 生成 1-(4-fluorobenzyl)-2-methyl-1H-benzimidazole-5-carboxylic acid
  参考文献：
  名称：

  Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist

  摘要：

  The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a ligand-activated nuclear receptor, thought to play a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation. A novel benzimidazole series of centrally penetrant PPAR gamma partial agonists has been identified. The optimization of PPAR gamma activity and in vivo pharmacokinetics leading to the identification of GSK1997132B a potent, metabolically stable and centrally penetrant PPAR gamma partial agonist, is described. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.088

文献信息

• AMIDE DERIVATIVE OR SALT THEREOF
  申请人：Kaku Hidetaka

  公开号：US20090062363A1

  公开（公告）日：2009-03-05

  [Problem] To provide a compound which can be used for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that an amide derivative characterized by the possession of a nitrogen-containing bicyclic hetero ring (e.g., an indole or the like), or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT 2B receptor and 5-HT 7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).

  [问题] 提供一种可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病的化合物，特别是用于治疗肠易激综合征（IBS）。 [解决方法] 发现一种具有含氮双环杂环（例如吲哚或类似物）的酰胺衍生物或其药学上可接受的盐具有强烈的5-HT2B受体和5-HT7受体的拮抗作用。此外，本发明的化合物具有对两种受体的拮抗活性，与仅使用选择性拮抗剂相比，表现出良好的药理作用。基于上述，本发明的化合物可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病，特别是用于治疗肠易激综合征（IBS）。
• EP1988076
  申请人：——

  公开号：——

  公开（公告）日：——
• US7985764B2
  申请人：——

  公开号：US7985764B2

  公开（公告）日：2011-07-26
• Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist
  作者：Mairi Sime、Amanda C. Allan、Paul Chapman、Charlotte Fieldhouse、Gerard M.P. Giblin、Mark P. Healy、Millard H. Lambert、Lisa M. Leesnitzer、Ann Lewis、Raymond V. Merrihew、Richard A. Rutter、Rosemary Sasse、Barry G. Shearer、Timothy M. Wilson、Robert X. Xu、David J. Virley

  DOI：10.1016/j.bmcl.2011.06.088

  日期：2011.9

  The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a ligand-activated nuclear receptor, thought to play a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation. A novel benzimidazole series of centrally penetrant PPAR gamma partial agonists has been identified. The optimization of PPAR gamma activity and in vivo pharmacokinetics leading to the identification of GSK1997132B a potent, metabolically stable and centrally penetrant PPAR gamma partial agonist, is described. (C) 2011 Elsevier Ltd. All rights reserved.